Following reports of RSV administration errors to the Therapeutic Goods Administration (TGA), 澳大利亚免疫登记 (AIR) and local vaccine safety surveillance systems, 安泰 has issued a statement reiterating appropriate product indications and recommendations.
The ATAGI Statement on Respiratory Syncytial Virus (RSV) immunisation products and prevention of administration errors includes guidance on the correct administration of RSV immunisation products and actions following inadvertent administration of the incorrect product.
Clinical guidance on the actions required following any RSV administration error has also been included in the Australian Immunisation Handbook.
Practices and immunisers should take appropriate steps to prevent errors, particularly in the context of a relatively new immunisation program. In the event of an error, the vaccinee or guardian should be informed via an open disclosure discussion. The error should also be reported to the jurisdiction’s vaccine safety service (SAEFVIC in Victoria).
Further support can be found via MVECs’ eLearning 疫苗错误：预防、管理和公开披露.